EXTENDED-RELEASE INJECTABLE BUPRENORPHINE FORMULATION SELECTION TOOL

BRIXADI®	Considerations	SUBLOCADE®
Patient must tolerate at least one dose of 4 mg transmucosal buprenorphine without precipitated withdrawal. *May provide a more efficient initiation pathway. 4 mg dose may appeal to those on lower doses or not currently taking TM buprenorphine.*	**Sublingual Buprenorphine Requirements Prior to Initiation**	Patient must tolerate ≥ 8 mg transmucosal buprenorphine daily for a minimum of 7 days. *Need for ≥ 8 mg daily dose and a minimum dosing period of 7 days may be a barrier to initiation.*
• Weekly*: 8mg/0.16mL, 16mg/0.32mL, 24mg/0.48mL, 32mg/0.64mL • Monthly: 64mg/0.18mL, 96mg/0.27mL, 128mg/0.36mL *Weekly doses cannot be combined to yield an equivalent monthly dose. *Greater dosing and frequency flexibility. Week 1 titration for BRIXADI® weekly in buprenorphine-naïve patients requires 2-3 injections.*	**Dosing**	2 monthly dosing options available: • 100mg/0.5mL • 300mg/1.5mL *Limited dosing options. Titration schedule is straightforward.*
• Half-life: ◦ Weekly: 3-5 days ◦ Monthly: 19-26 days • Detectable levels after steady-state achieved: ◦ Weekly: 1 month ◦ Monthly: 4 months *Shorter lasting and lower sustained plasma levels.*	**Pharmacokinetics**	• Half-life: ◦ 43-60 days • Detectable levels after steady-state achieved: ◦ ≥ 12 months in plasma and urine *Longer lasting and higher sustained plasma levels may be helpful if monthly adherence is a concern.*
Subcutaneous injection into the abdomen, thigh, buttock, and upper arm*. *Upper arm site is associated with approximately 10% lower plasma levels than other sites. *More injection site options beneficial for those with limited abdominal fat or seeking a less visible site than abdomen.*	**Site(s) of Administration**	Subcutaneous injection into the abdomen only. *Adequate adipose tissue required for abdominal administration.*
23-gauge, 1/2-inch needle *Smaller and thinner needle, along with less volume, may result in less painful injections.*	**Needle Size**	19-gauge, 5/8-inch needle *100 mg dose is typically better tolerated due to smaller needle and less volume vs 300 mg.*
Depot cannot be removed once medication is administered. *Depots are typically small and dissolve within a few weeks.*	**Depot Removal**	Depot can be surgically removed within 14 days of administration. *Removal option for depot in case of severe injection site reactions or intolerance.*
• Latex allergy: BRIXADI® needle cap synthetically derived from natural rubber latex. • Soybean allergy: BRIXADI® contains soybean.	**Allergy Considerations**	No known allergies associated with SUBLOCADE® ingredients.
Use with caution; ongoing clinical trial (MOMs study) evaluating use of BRIXADI® in pregnancy. Avoid injections in the abdomen during pregnancy.	**Use in Pregnancy**	Use with caution; SUBLOCADE® has not been studied for use in pregnancy.